IGBA Aims To Take The Fight To Originators On Trade Deals
With a permanent structure in place and a trade principles paper recently updated, the IGBA believes it is well placed to argue the case for promoting accessible medicines in international trade negotiations versus the interests of the originator industry.
You may also be interested in...
A series of global policy recommendations has been set out by the International Generic and Biosimilar Medicines Association as part of efforts to ensure a sustainable industry environment and maintain patient access to off-patent drugs.
The UK’s main opposition party, Labour, says it would resist US pressure to raise intellectual-property protections for pharmaceuticals. And it wants to support other countries in ensuring trade negotiations do not result in stronger IP rights globally.
More than 100 members of the US Congress have written to US Trade Representative ambassador Robert Lighthizer urging changes to the US-Mexico-Canada Agreement trade deal that is due to replace the previous NAFTA agreement, with biologic competition and access highlighted as key concerns.